Physician profile
Christopher J Nero
NPI 1548396377
$1,168.63
in general payments reported to CMS, 2019-2025
14 companies · $257 in 2025
The $257 reported for 2025 was more than what 82% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.25 · 2022: $37.56 · 2023: $459 · 2024: $396 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $309.97 | 2023-2025 | Tecvayli, Darzalex, Talvey |
| Lilly USA, LLC | $257.98 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Astrazeneca Pharmaceuticals Lp | $108.09 | 2024-2025 | Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $89.01 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Stemline Therapeutics INC. | $85.06 | 2024-2025 | Orserdu |
| Caris Mpi, INC. | $66.30 | 2025 | Mi Cancer Seek |
| Pharming Healthcare, INC. | $46.40 | 2023 | Ruconest |
| Roche Diagnostics Corporation | $43.44 | 2021-2024 | Benchmark Ultra |
| Servier Pharmaceuticals LLC | $38.47 | 2023-2024 | |
| Emd Serono, INC. | $37.13 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $34.40 | 2025 | Libtayo |
| Genentech USA, INC. | $20.82 | 2024 | Tecentriq |
| Abbott Laboratories | $16.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.65 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.